Axicabtagene Ciloleucel Expanded Access Study

Summary

A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma. Subjects who received an infusion of axicabtagene ciloleucel will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications